The Efficacy of Patient-dependent Practices on Exposure Rate in Patients Undergoing Iodine-131 Ablation
- 1 May 2013
- journal article
- Published by Wolters Kluwer Health in Health Physics
- Vol. 104 (5) , 454-458
Abstract
The authors investigated the efficacy of the patient-dependent practices (micturition, defecation, and taking a shower) after I ablation therapy in patients with thyroid cancer. Exposure rates were measured from a 1-m distance at 2, 4, and 24 h after the I administration. The comparisons for 2-4 h and 2-24 h time intervals were carried out among the patients with good and poor compliance, according to the relative amount of the patient-dependent practices, over mean values calculated for an effective half-life (h) or exposure rate decline ratio (%). In the 2-4 h interval, the mean values for good versus poor compliance were found to be: 4.16 h versus 8.14 h and 31% versus 17% in micturition; 5.70 h versus 6.84 h and 26% versus 21% in defecation; and 6.68 h versus 5.69 h and 24% versus 24% in taking a shower. Among patients with good versus poor compliance during a 2-24 h interval, the mean values were: 11.63 h versus 16.62 h and 74% versus 61% in micturition; 12.75 h versus 15.88 h and 71% versus 63% in defecation; and 13.77 h versus 14.21 h and 68% versus 67% in taking a shower.Keywords
This publication has 9 references indexed in Scilit:
- Iodine Biokinetics and Radioiodine Exposure after Recombinant Human Thyrotropin-Assisted Remnant Ablation in Comparison with Thyroid Hormone WithdrawalThe Journal of Clinical Endocrinology & Metabolism, 2010
- Estimation of effective half life of clearance of radioactive Iodine ( 131 I) in patients treated for hyperthyroidism and carcinoma thyroidIndian Journal of Nuclear Medicine, 2010
- Liquid discharges from patients undergoing 131I treatmentsJournal of Environmental Radioactivity, 2008
- 131I Effective Half-Life and Dosimetry in Thyroid Cancer PatientsJournal of Nuclear Medicine, 2008
- EVALUATION OF THE POTENTIAL ABSORBED DOSES FROM PATIENTS BASED ON WHOLE-BODY 131I CLEARANCE IN THYROID CANCER THERAPYHealth Physics, 2006
- 131I EFFECTIVE HALF-LIFE (Teff) FOR PATIENTS WITH THYROID CANCERHealth Physics, 2006
- Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirementsNuclear Medicine Communications, 2005
- Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinomaNuclear Medicine Communications, 2001
- EFFECTIVE HALF-LIFE OF 131I IN THYROID CANCER PATIENTSHealth Physics, 2001